# | Title | Journal | Year | Citations |
---|
1 | The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months | Pharmacoepidemiology and Drug Safety | 2007 | 1,338 |
2 | Validation of the national health insurance research database with ischemic stroke cases in Taiwan | Pharmacoepidemiology and Drug Safety | 2011 | 1,139 |
3 | Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports | Pharmacoepidemiology and Drug Safety | 2001 | 1,018 |
4 | Methods for evaluation of medication adherence and persistence using automated databases | Pharmacoepidemiology and Drug Safety | 2006 | 867 |
5 | A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions | Pharmacoepidemiology and Drug Safety | 2002 | 822 |
6 | Increasing deaths from opioid analgesics in the United States | Pharmacoepidemiology and Drug Safety | 2006 | 620 |
7 | Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics | Pharmacoepidemiology and Drug Safety | 2006 | 585 |
8 | Quantitative signal detection using spontaneous ADR reporting | Pharmacoepidemiology and Drug Safety | 2009 | 551 |
9 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research | Pharmacoepidemiology and Drug Safety | 2007 | 535 |
10 | The reporting odds ratio and its advantages over the proportional reporting ratio | Pharmacoepidemiology and Drug Safety | 2004 | 486 |
11 | Trends in long‐term opioid therapy for chronic non‐cancer pain | Pharmacoepidemiology and Drug Safety | 2009 | 484 |
12 | Immortal time bias in observational studies of drug effects | Pharmacoepidemiology and Drug Safety | 2007 | 462 |
13 | The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology | Pharmacoepidemiology and Drug Safety | 2017 | 382 |
14 | One‐to‐many propensity score matching in cohort studies | Pharmacoepidemiology and Drug Safety | 2012 | 373 |
15 | Increasing off‐label use of antipsychotic medications in the United States, 1995–2008 | Pharmacoepidemiology and Drug Safety | 2011 | 365 |
16 | A synthesis of oral morphine equivalents (OME) for opioid utilisation studies | Pharmacoepidemiology and Drug Safety | 2016 | 322 |
17 | Principles for modeling propensity scores in medical research: a systematic literature review | Pharmacoepidemiology and Drug Safety | 2004 | 296 |
18 | Hy's law: predicting serious hepatotoxicity | Pharmacoepidemiology and Drug Safety | 2006 | 294 |
19 | An automated database case definition for serious bleeding related to oral anticoagulant use | Pharmacoepidemiology and Drug Safety | 2011 | 291 |
20 | The relationship between time since registration and measured incidence rates in the General Practice Research Database | Pharmacoepidemiology and Drug Safety | 2005 | 289 |
21 | Instrumental variable methods in comparative safety and effectiveness research | Pharmacoepidemiology and Drug Safety | 2010 | 288 |
22 | Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three‐year period in an elderly population | Pharmacoepidemiology and Drug Safety | 2011 | 284 |
23 | Guidelines for good database selection and use in pharmacoepidemiology research | Pharmacoepidemiology and Drug Safety | 2012 | 283 |
24 | A systematic review of validated methods for identifying atrial fibrillation using administrative data | Pharmacoepidemiology and Drug Safety | 2012 | 280 |
25 | Adverse drug events in the outpatient setting: an 11‐year national analysis | Pharmacoepidemiology and Drug Safety | 2010 | 260 |
26 | The importance of defining periods of complete mortality reporting for research using automated data from primary care | Pharmacoepidemiology and Drug Safety | 2009 | 259 |
27 | Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data | Pharmacoepidemiology and Drug Safety | 2011 | 259 |
28 | Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making | Pharmacoepidemiology and Drug Safety | 2017 | 251 |
29 | Recent changes in drug poisoning mortality in the United States by urban–rural status and by drug type | Pharmacoepidemiology and Drug Safety | 2008 | 250 |
30 | On principles for modeling propensity scores in medical research | Pharmacoepidemiology and Drug Safety | 2004 | 248 |
31 | Further validation of information recorded on a general practitioner based computerized data resource in the united kingdom | Pharmacoepidemiology and Drug Safety | 1992 | 241 |
32 | Estimates of acetaminophen (paracetomal)-associated overdoses in the United States | Pharmacoepidemiology and Drug Safety | 2006 | 239 |
33 | Trends in the use of aspirin and nonsteroidal anti‐inflammatory drugs in the general U.S. population | Pharmacoepidemiology and Drug Safety | 2014 | 235 |
34 | Hospitalisations and emergency department visits due to drug–drug interactions: a literature review | Pharmacoepidemiology and Drug Safety | 2007 | 233 |
35 | A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data | Pharmacoepidemiology and Drug Safety | 2012 | 224 |
36 | A basic study design for expedited safety signal evaluation based on electronic healthcare data | Pharmacoepidemiology and Drug Safety | 2010 | 223 |
37 | Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project | Pharmacoepidemiology and Drug Safety | 2011 | 222 |
38 | A systematic review of validated methods for identifying heart failure using administrative data | Pharmacoepidemiology and Drug Safety | 2012 | 209 |
39 | Use of herbal drugs in pregnancy: a survey among 400 Norwegian women | Pharmacoepidemiology and Drug Safety | 2004 | 206 |
40 | Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations | Pharmacoepidemiology and Drug Safety | 2007 | 206 |
41 | Design considerations, architecture, and use of the Mini‐Sentinel distributed data system | Pharmacoepidemiology and Drug Safety | 2012 | 204 |
42 | Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta‐analysis | Pharmacoepidemiology and Drug Safety | 2014 | 204 |
43 | Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients | Pharmacoepidemiology and Drug Safety | 2008 | 203 |
44 | Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies | Pharmacoepidemiology and Drug Safety | 2005 | 202 |
45 | The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan | Pharmacoepidemiology and Drug Safety | 2019 | 200 |
46 | QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system | Pharmacoepidemiology and Drug Safety | 2005 | 198 |
47 | Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States | Pharmacoepidemiology and Drug Safety | 2007 | 198 |
48 | Guidelines for good pharmacoepidemiology practices (GPP) | Pharmacoepidemiology and Drug Safety | 2008 | 195 |
49 | Evaluating uses of data mining techniques in propensity score estimation: a simulation study | Pharmacoepidemiology and Drug Safety | 2008 | 195 |
50 | Prescription drug use during pregnancy in developed countries: a systematic review | Pharmacoepidemiology and Drug Safety | 2011 | 189 |